At the "What Is New in Psoriatic Arthritis" session at EULAR 2026, Professor Dennis McGonagle (Leeds, UK) took the audience on a whirlwind yet compact tour of the field, touching on three themes: the pathophysiology of PsA, individualization of clinical management, and emerging research and future directions.
All News
Article
Antoni Chan MD (Prof)
Tweet
Double targeted therapy in refractory SpA/PsA.
76 patients, 17 Spanish centres, up to 6 years follow-up. Median 4 prior biologics.
Remission achieved in 55.6% during follow-up. 28.6% in remission at final visit.
ASDAS improved significantly from 3 months, sustained to 5 https://t.co/g1IPstYYuX
sheila
Tweet
10yr ffup data on 49pts from the OG CRESPA study (GOL vs PBO in very early pSpA):
81.6% (40/49) were in clinical remission
15 pts on drug-free remission
21 pts w/remission on meds still on GOL, no unSSAEs
Early aggressive tx is key!
AbsPOS0931 @RheumNow #EULAR2026 https://t.co/HrTF5XtAZt
Antoni Chan MD (Prof)
Tweet
PET-derived parameters in #PsA correlated with DAPSA, CRP and patient pain. Angiogenesis imaging may be a complementary biomarker of overall disease burden Abstr#OP068 #EULAR2026 #Imaging
Antoni Chan MD (Prof)
Tweet
Treat-to-target in inflammatory arthritis recommended by every guideline. Followed in only 40% of SpA visits.
The main reason was activity simply wasnโt documented using a validated index.
You canโt target what you donโt measure.
Abstr 0351 @ RheumNow #EULAR2026
#axSpA #PsA https://t.co/VAcoZfCXsR
๐ฎ Can polygenic risk scores predict PsA timing in psoriasis?
Another GWAS study (n=703) says YES!
70-SNP model achieves AUC 0.843 for predicting PsA onset <10 vs >10 years
#POS0088 #EULAR2026 @RheumNow https://t.co/wI4Jy8Yu2A
๐ฅ TOGETHER-PsA (OP069) #EULAR2026 #EULARbest Ixekizumab + Tirzepatide vs IXE alone in PsA with obesity/overweight: โ Primary endpoint (ACR50 + โฅ10% wt loss at W36): 31.7% vs. 0.8% (p<0.001) โ ACR50: 33.5% vs. 20.4% โ MDA: 26.3% vs. 15.3% (p=0.026) @rheumnow @DrLauraCoates https://t.co/6wh3S6khXw
๐ฌ Can baseline T cell phenotype predict PsA treatment response?
COLIPSO cohort (n=17): YES!
Higher Treg & activated CD4+ cells predict DAPSA & joint improvement
#POS0083 #EULAR2026 @RheumNow https://t.co/UIs6LXAWAY
โ๏ธ Does BMI outrank treatment in early PsA outcomes?
YES - SPEED trial AI analysis:
BMI #1 predictor of PASDAS at 1yr in 192pts
#OP0187 #EULAR2026 @RheumNow https://t.co/9cZG7AWau2
๐ Does bimekizumab work in real-world PsA?
YES - EuroSpA: 76% retention at 6months
46% DAPSA LDA in 787pts across 12 registries
#OP0185 #EULAR2026 @RheumNow https://t.co/TXS3r9mZXB
๐งฒ Does GUS+GOL combo beat GUS alone on MRI in PsA?
YES for joints - AFFINITY Phase 2a RCT: greater MRI inflammation reduction in 91pts
#OP0186 #EULAR2026 @RheumNow https://t.co/9eIS6lh7WN
๐งฌ Do biomarkers predict #zasocitinib response in PsA?
YES: TYK2/IL-17 pathway markers predict ACR20 in 290pts Phase 2b RCT
#OP0184 #EULAR2026 @RheumNow https://t.co/AVlyrauI5q
๐ Can US predict PsA progression from psoriasis?
YES: synovio-entheseal inflammation predicts progression in 183pts prospective cohort
#OP0183 #EULAR2026 @RheumNow https://t.co/7B9KU60qFd
๐ฆด What drives enthesophytes in PsA?
SITE-SPECIFIC:
Pelvic driven by disease activity+BMI
Calcaneal by BMI+damage
in a 1596pts cohort
OP0182 #EULAR2026 @RheumNow https://t.co/4RxgjJ2V9u
โค๏ธ Do biologics differ in MACE risk in PsA?
YES - JAKi highest risk after 2.5yrs vs TNFi/IL-17i/IL-23i in a retrospective cohort of 22,246pts.
OP0181 #EULAR2026 @RheumNow https://t.co/eQdBtMfRAY
After TNFi secondary failure: does MOA switch beat TNFi cycling? UK RWD (n=155): yes for #PsA (76% vs 57% drug survival at 12m) and axSpA (80% vs 68%), but not RA. Yet 74% of axSpA pts still got another TNFi. Evidence vs practice gap in plain sight. @RheumNow #EULAR2026 POS0776
Real-world bimekizumab in SpA/#PsA (BIMPACT, n=223): 76% retention at 12mo, even with 54% having prior IL-17i exposure. Effective after IL-17Ai failure. Oral candidiasis higher in PsA (16.5%) vs SpA (3.3%); led to discontinuation in ~25%. @RheumNow #EULAR2026 POS0798/POS0810
sheila
Tweet
Impt pts to consider in D2T CLE by Prof Wittmann:
If tx is not working, ask yourself: is the dx correct? adherence?
Main message: treat early
When damage is present, tx doesnโt really provide considerable improvements
Future drxns? Endotype-directed tx
@Rheumnow #EULAR2026 https://t.co/hB48aD7jx5
